Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.38 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | GAK | O14976 | 2/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.34 |
| ▸ | COQ8A | Q8NI60 | 2/20 | 0.34 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478742 | 0.84 | MBOAT4 (0.41) | CETPMBOAT4MGLLGAKRIPK2 | |
| SCHEMBL21290713 | 0.84 | MBOAT4 (0.41) | CETPMBOAT4MGLLGAKRIPK2 | |
| SCHEMBL22637777 | 0.83 | MBOAT4 (0.39) | MBOAT4CCNCCDK8GAKRIPK2 | |
| SCHEMBL7219031 | 0.77 | KDM4E (0.49) | MBOAT4CCNCCDK8HRH4CYP19A1 | |
| SCHEMBL4103686 | 0.76 | MBOAT4 (0.40) | MBOAT4CCNCCDK8HRH4MAP3K12 | |
| SCHEMBL4927528 | 0.74 | CETP (0.42) | CETPHRH4MAP3K12JAK2JAK3 | |
| SCHEMBL4963448 | 0.74 | MBOAT4 (0.40) | MBOAT4CCNCCDK8GAKRIPK2 | |
| SCHEMBL3869976 | 0.74 | CCNC (0.40) | MBOAT4CCNCCDK8GAKRIPK2 | |
| SCHEMBL3870198 | 0.74 | CCNC (0.40) | MBOAT4CCNCCDK8GAKRIPK2 | |
| SCHEMBL3242600 | 0.73 | CYP1A2 (0.44) | MBOAT4CCNCCDK8MAP3K12CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| US-20210053946-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-02-25 | — | — | US | disclosed |
| US-10710986-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190345131-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2019204609-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20190270727-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-09-05 | — | — | US | disclosed |
| WO-2019160882-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | CETP 3920/4885MBOAT4 3765/4885CCNC 495/4885 |
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CETP 3387/4885MBOAT4 3922/4885CCNC 419/4885 |
| US-20210053946-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CETP 3387/4885MBOAT4 3922/4885CCNC 419/4885 |
| US-20190345131-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CETP 3833/4885MBOAT4 3536/4885CCNC 436/4885 |
| US-10710986-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | CETP 3387/4885MBOAT4 3922/4885CCNC 419/4885 |
| US-20190270727-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CETP 3387/4885MBOAT4 3922/4885CCNC 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.